Prognostic value of late gadolinium enhancement cardiovascular magnetic resonance in cardiac amyloidosis

Circulation

Volumn 132, Issue 16, 2015, Pages 1570-1579

  Fontana, Marianna ^a,b   Pica, Silvia ^a   Reant, Patricia ^a   Abdel Gadir, Amna ^a,b   Treibel, Thomas A ^a,b   Banypersad, Sanjay M ^b   Maestrini, Viviana ^a   Barcella, William ^b   Rosmini, Stefania ^a   Bulluck, Heerajnarain ^a,b   Sayed, Rabya H ^b   Patel, Ketna ^b   Mamhood, Shameem ^b   Bucciarelli Ducci, Chiara ^c   Whelan, Carol J ^b   Herrey, Anna S ^a   Lachmann, Helen J ^b   Wechalekar, Ashutosh D ^b   Manisty, Charlotte H ^a   Schelbert, Eric B ^d   Kellman, Peter ^e   Gillmore, Julian D ^b   Hawkins, Philip N ^b   Moon, James C ^a,b   more..

^a UNIVERSITY COLLEGE LONDON HOSPITALS   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

^c UNIVERSITY OF BRISTOL   (United Kingdom)

^d UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^e NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

Author keywords

amyloidosis; cardiac imaging techniques; magnetic resonance imaging; prognosis

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; GADOLINIUM;

AGED; ARTICLE; CARDIOVASCULAR MAGNETIC RESONANCE; CONTRAST ENHANCEMENT; CONTROLLED STUDY; CORRELATIONAL STUDY; EXTRACELLULAR SPACE; FEMALE; FOLLOW UP; HEART AMYLOIDOSIS; HEART EJECTION FRACTION; HEART LEFT VENTRICLE MASS; HEART STROKE VOLUME; HUMAN; LATE GADOLINIUM ENHANCEMENT; MAJOR CLINICAL STUDY; MALE; NUCLEAR MAGNETIC RESONANCE SCANNER; PHASE SENSITIVE INVERSION RECOVERY; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROSPECTIVE STUDY; RADIOLOGICAL PARAMETERS; AMYLOIDOSIS; CARDIAC MUSCLE; CARDIOMYOPATHIES; IMAGE ENHANCEMENT; MIDDLE AGED; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOLOGY; PROCEDURES;

AGED; AMYLOIDOSIS; CARDIOMYOPATHIES; FEMALE; GADOLINIUM; HUMANS; IMAGE ENHANCEMENT; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; MYOCARDIUM; PROGNOSIS;

EID: 84945460974     PISSN: 00097322     EISSN: 15244539     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.115.016567     Document Type: Article

References (27)

1. Falk RH, Comenzo RL, Skinner M, The systemic amyloidoses. N Engl J Med 1997 337 898 909. doi: 10.1056/NEJM199709253371306.
2. Rapezzi C, Merlini G, Quarta CC, Riva L, Longhi S, Leone O, Salvi F, Ciliberti P, Pastorelli F, Biagini E, Coccolo F, Cooke RM, Bacchi-Reggiani L, Sangiorgi D, Ferlini A, Cavo M, Zamagni E, Fonte ML, Palladini G, Salinaro F, Musca F, Obici L, Branzi A, Perlini S, Systemic cardiac amyloidoses: disease profiles and clinical courses of the 3 main types. Circulation 2009 120 1203 1212. doi: 10.1161/CIRCULATIONAHA.108.843334.
3. Dispenzieri A, Gertz MA, Kyle RA, Lacy MQ, Burritt MF, Therneau TM, Greipp PR, Witzig TE, Lust JA, Rajkumar SV, Fonseca R, Zeldenrust SR, McGregor CG, Jaffe AS, Serum cardiac troponins and N-Terminal pro-brain natriuretic peptide: a staging system for primary systemic amyloidosis. J Clin Oncol 2004 22 3751 3757. doi: 10.1200/JCO.2004.03.029.
4. Wechalekar AD, Schonland SO, Kastritis E, Gillmore JD, Dimopoulos MA, Lane T, Foli A, Foard D, Milani P, Rannigan L, Hegenbart U, Hawkins PN, Merlini G, Palladini G, A European collaborative study of treatment outcomes in 346 patients with cardiac stage III AL amyloidosis. Blood 2013 121 3420 3427. doi: 10.1182/blood-2012-12-473066.
5. Dubrey SW, Cha K, Skinner M, LaValley M, Falk RH, Familial and primary (AL) cardiac amyloidosis: echocardiographically similar diseases with distinctly different clinical outcomes. Heart 1997 78 74 82
6. Palladini G, Campana C, Klersy C, Balduini A, Vadacca G, Perfetti V, Perlini S, Obici L, Ascari E, d'Eril GM, Moratti R, Merlini G, Serum N-Terminal pro-brain natriuretic peptide is a sensitive marker of myocardial dysfunction in AL amyloidosis. Circulation 2003 107 2440 2445. doi: 10.1161/01.CIR.0000068314.02595.B2.
7. Sayed RH, Rogers D, Khan F, Wechalekar AD, Lachmann HJ, Fontana M, Mahmood S, Sachchithanantham S, Patel K, Hawkins PN, Whelan CJ, Gillmore JD, A study of implanted cardiac rhythm recorders in advanced cardiac AL amyloidosis. Eur Heart J 2015 36 1098 1105. doi: 10.1093/eurheartj/ehu506.
8. 123I-labeled serum amyloid P component. N Engl J Med 1990 323 508 513. doi: 10.1056/NEJM199008233230803.
9. Kwong RY, Jerosch-Herold M, CMR and amyloid cardiomyopathy: are we getting closer to the biology? JACC Cardiovasc Imaging 2014 7 166 168. doi: 10.1016/j.jcmg.2013.12.002.
10. Maceira AM, Joshi J, Prasad SK, Moon JC, Perugini E, Harding I, Sheppard MN, Poole-Wilson PA, Hawkins PN, Pennell DJ, Cardiovascular magnetic resonance in cardiac amyloidosis. Circulation 2005 111 186 193. doi: 10.1161/01.CIR.0000152819.97857.9D.
11. Kwong RY, Falk RH, Cardiovascular magnetic resonance in cardiac amyloidosis. Circulation 2005 111 122 124. doi: 10.1161/01.CIR.0000153623.02240.20.
12. Dungu JN, Valencia O, Pinney JH, Gibbs SD, Rowczenio D, Gilbertson JA, Lachmann HJ, Wechalekar A, Gillmore JD, Whelan CJ, Hawkins PN, Anderson LJ, CMR-based differentiation of AL and ATTR cardiac amyloidosis. JACC Cardiovasc Imaging 2014 7 133 142. doi: 10.1016/j.jcmg.2013.08.015.
13. Vogelsberg H, Mahrholdt H, Deluigi CC, Yilmaz A, Kispert EM, Greulich S, Klingel K, Kandolf R, Sechtem U, Cardiovascular magnetic resonance in clinically suspected cardiac amyloidosis: noninvasive imaging compared to endomyocardial biopsy. J Am Coll Cardiol 2008 51 1022 1030. doi: 10.1016/j.jacc.2007.10.049.
14. Maceira AM, Prasad SK, Hawkins PN, Roughton M, Pennell DJ, Cardiovascular magnetic resonance and prognosis in cardiac amyloidosis. J Cardiovasc Magn Reson 2008 10 54. doi: 10.1186/1532-429X-10-54.
15. Austin BA, Tang WH, Rodriguez ER, Tan C, Flamm SD, Taylor DO, Starling RC, Desai MY, Delayed hyper-enhancement magnetic resonance imaging provides incremental diagnostic and prognostic utility in suspected cardiac amyloidosis. JACC Cardiovasc Imaging 2009 2 1369 1377. doi: 10.1016/j.jcmg.2009.08.008.
16. Ruberg FL, Appelbaum E, Davidoff R, Ozonoff A, Kissinger KV, Harrigan C, Skinner M, Manning WJ, Diagnostic and prognostic utility of cardiovascular magnetic resonance imaging in light-chain cardiac amyloidosis. Am J Cardiol 2009 103 544 549. doi: 10.1016/j.amjcard.2008.09.105.
17. Mekinian A, Lions C, Leleu X, Duhamel A, Lamblin N, Coiteux V, De Groote P, Hatron PY, Facon T, Beregi JP, Hachulla E, Launay D, Lille Amyloidosis Study Group Prognosis assessment of cardiac involvement in systemic AL amyloidosis by magnetic resonance imaging. Am J Med 2010 123 864 868. doi: 10.1016/j.amjmed.2010.03.022.
18. Syed IS, Glockner JF, Feng D, Araoz PA, Martinez MW, Edwards WD, Gertz MA, Dispenzieri A, Oh JK, Bellavia D, Tajik AJ, Grogan M, Role of cardiac magnetic resonance imaging in the detection of cardiac amyloidosis. JACC Cardiovasc Imaging 2010 3 155 164. doi: 10.1016/j.jcmg.2009.09.023.
19. White JA, Kim HW, Shah D, Fine N, Kim KY, Wendell DC, Al-Jaroudi W, Parker M, Patel M, Gwadry-Sridhar F, Judd RM, Kim RJ, CMR imaging with rapid visual T1 assessment predicts mortality in patients suspected of cardiac amyloidosis. JACC Cardiovasc Imaging 2014 7 143 156. doi: 10.1016/j.jcmg.2013.09.019.
20. Kellman P, Arai AE, McVeigh ER, Aletras AH, Phase-sensitive inversion recovery for detecting myocardial infarction using gadolinium-delayed hyperenhancement. Magn Reson Med 2002 47 372 383
21. Piechnik SK, Ferreira VM, Dall'Armellina E, Cochlin LE, Greiser A, Neubauer S, Robson MD, Shortened modified look-locker inversion recovery (ShMOLLI) for clinical myocardial T1-mapping at 1.5 and 3 T within a 9 heartbeat breathhold. J Cardiovasc Magn Reson 2010 12 69. doi: 10.1186/1532-429X-12-69.
22. Fontana M, White SK, Banypersad SM, Sado DM, Maestrini V, Flett AS, Piechnik SK, Neubauer S, Roberts N, Moon JC, Comparison of T1 mapping techniques for ECV quantification: histological validation and reproducibility of ShMOLLI versus multibreath-hold T1 quantification equilibrium contrast CMR. J Cardiovasc Magn Reson 2012 14 88. doi: 10.1186/1532-429X-14-88.
23. Kellman P, Arai AE, Cardiac imaging techniques for physicians: late enhancement. J Magn Reson Imaging 2012 36 529 542. doi: 10.1002/jmri.23605.
24. Mongeon FP, Jerosch-Herold M, Coelho-Filho OR, Blankstein R, Falk RH, Kwong RY, Quantification of extracellular matrix expansion by CMR in infiltrative heart disease. JACC Cardiovasc Imaging 2012 5 897 907. doi: 10.1016/j.jcmg.2012.04.006.
25. Barison A, Aquaro GD, Pugliese NR, Cappelli F, Chiappino S, Vergaro G, Mirizzi G, Todiere G, Passino C, Masci PG, Perfetto F, Emdin M, Measurement of myocardial amyloid deposition in systemic amyloidosis: insights from cardiovascular magnetic resonance imaging. J Intern Med 2015 277 605 614. doi: 10.1111/joim.12324.
26. Fontana M, Banypersad SM, Treibel TA, Abdel-Gadir A, Maestrini V, Lane T, Gilbertson JA, Hutt DF, Lachmann HJ, Whelan CJ, Wechalekar AD, Herrey AS, Gillmore JD, Hawkins PN, Moon JC, Differential myocyte responses in patients with cardiac transthyretin amyloidosis and light-chain amyloidosis: a cardiac MR imaging study [published online ahead of print May 21, 2015]. Radiology. 2015 May 21:141744. doi: http://dx.doi.org/10.1148/radiol.2015141744. http://pubs.rsna.org/doi/10.1148/radiol.2015141744?url ver=Z39.88-2003&rfrid=ori%3Arid%3Acrossref.org&rfr-dat=cr-pub%3Dpubmed&. Accessed September 20, 2015
27. Banypersad SM, Fontana M, Maestrini V, Sado DM, Captur G, Petrie A, Piechnik SK, Whelan CJ, Herrey AS, Gillmore JD, Lachmann HJ, Wechalekar AD, Hawkins PN, Moon JC, T1 mapping and survival in systemic light-chain amyloidosis. Eur Heart J 2015 36 244 251. doi: 10.1093/eurheartj/ehu444.